We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...

In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Amicus (FOLD – Research Report), with a price ...

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics (PTCT) to $76 from $80 and keeps an Overweight rating on the shares. The ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald from ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Nova (NasdaqGS:NVMI) with a Overweight ...

We recently compiled a list of the 14 AI Stocks Making Waves on Wall Street. In this article, we are going to take a look at ...

Stock analysts at Cantor Fitzgerald dropped their FY2024 earnings per share estimates for Maplebear in a research note issued on Tuesday, January 7th. Cantor Fitzgerald analyst D. Mathivanan now ...

Fintel reports that on January 10, 2025, Cantor Fitzgerald initiated coverage of Voyager Therapeutics (NasdaqGS:VYGR) with a Overweight recommendation. As of December 23, 2024, the average one ...

NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Cantor Equity Partners I, Inc. (Nasdaq: CEPO) (the "Company") announced today that it closed its initial public offering of 20,000,000 Class A ordinary ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...